卫非特 | 161935-14-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 中文名称: 卫非特
• 英文名称: Trifazid
• 英文别名: [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate;pyrazine-2-carboxamide;pyridine-4-carbohydrazide
• CAS: 161935-14-4
• 化学式: C54H70N10O14
• 分子量: 1083.2
• InChiKey: KVPNBBUKZBDNBJ-OIXVRUHCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  78
• 可旋转键数：
  7
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  357
• 氢给体数：
  9
• 氢受体数：
  21

文献信息

• Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation
  申请人：——

  公开号：US20030072800A1

  公开（公告）日：2003-04-17

  A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation caused by presence of Isoniazid. Rifampicin and/or Isoniazid may be present in delayed release and/or extended release form such that minimal amount of the drug is dissolved between pH 1 and 4. preferably delayed release of Rifampicin and/or Isoniazid is achieved by treating the drugs with pH sensitive polymers.

  一种口服抗结核药物组合物，包括利福平和/或异烟肼，其中利福平和/或其他药物的生物利用度得到提高。最好是通过防止因异烟肼的存在而引起的利福平降解来提高利福平的生物利用度。利福平和/或异烟肼可以缓释和/或缓释形式存在，这样在 pH 值为 1 和 4 之间溶解的药物量极少，最好通过使用对 pH 值敏感的聚合物处理药物来实现利福平和/或异烟肼的缓释。
• Hepatocurative effect of emblica officinalis against CYP 450 bio-activation hepatotoxicity of drugs
  申请人：——

  公开号：US20030185922A1

  公开（公告）日：2003-10-02

  The present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and method of treating drug induced hepatotoxicity

  本发明涉及一种对药物诱导的 CYP 450 生物活化肝毒性具有抗肝毒性作用的组合物，所述组合物包含一种从以下植物中提取的提取物 大蒜提取物 和可选的药学上可接受的添加剂，以及治疗药物诱导的肝毒性的方法
• PHARMACEUTICAL COMPOSITIONS OF ANTI-TUBERCULAR DRUGS AND PROCESS FOR THEIR PREPARATION
  申请人：Panacea Biotec Limited

  公开号：EP1307199A2

  公开（公告）日：2003-05-07
• Hepatocurative effect of Emblica officinalis against CYP 450 bio-activation hepatotoxicity of drugs
  申请人：Johri Kamal Rakesh

  公开号：US20060121138A1

  公开（公告）日：2006-06-08

  The present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and method of treating drug induced hepatotoxicity.
• US7001619B2
  申请人：——

  公开号：US7001619B2

  公开（公告）日：2006-02-21